EVX
VanEck Environmental Services ETF
Set alert
- YTD
- +5.46%
- 1 year
- +8.59%
- Open
- 40.33
- Prev close
- 40.42
- Mkt cap
- 99.07M
- Vol
- 9.97K
- Avg vol
- 7.04K
- EPS
- 1.53
- P/E
- 26.32
- Div yield
- 0.00%
More statistics
- Low
- 40.12
- High
- 40.71
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 184.91
- 200-d avg
- 173.93
News
1 week ago globenewswire.com
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, October 23, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform,…
1 week ago globenewswire.com
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform,…
3 weeks ago marketbeat.com
These 3 ETFs Could Benefit From the Parts of Inflation That Won't Go Away
It's not just the cost of goods that is rising, although inflation remains a persistent source of consumer frustration. The U.S. services sector saw growth cool in September, even as domestic demand…
4 weeks ago globenewswire.com
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will…
2 months ago globenewswire.com
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it…
3 months ago globenewswire.com
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present…
3 months ago globenewswire.com
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data…
4 months ago globenewswire.com
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present new…
4 months ago globenewswire.com
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new…
5 months ago globenewswire.com
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the…
10 months ago businesswire.com
VanEck Announces Year-End Distributions for VanEck Equity ETFs
NEW YORK--(BUSINESS WIRE)--VanEck announced today the 2025 annual distributions per share for its VanEck equity exchange-traded funds.
11 months ago newsfilecorp.com
European Electric Metals to Acquire Miminiska Gold Property in Ontario, Name Change to Canadian Goldfields Discovery Corp. and Appointment of John Booth as CEO
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - European Electric Metals Inc. (TSXV: EVX) (the "Company") is pleased to announce that it has entered into a mineral property…
11 months ago accessnewswire.com
Storm Exploration Enters Agreement to Sell the Miminiska Project
VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / Storm Exploration Inc. (TSXV:STRM) ("Storm" or the "Company") is pleased to announce that it has entered into a mineral property purchase…
11 months ago globenewswire.com
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data…
1 year ago newsfilecorp.com
European Electric Metals Announces Resumption of Trading
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - European Electric Metals Inc. (TSXV: EVX) (the "Company") announces that trading of the Company's common shares on the TSX Venture…
1 year ago globenewswire.com
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, October 17, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new two-year…
1 year ago globenewswire.com
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
COPENHAGEN, Denmark, October 13, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present a wide range…
1 year ago globenewswire.com
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
COPENHAGEN, Denmark, October 3, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data for…
1 year ago globenewswire.com
Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year…
1 year ago benzinga.com
Ecolab Navigates Soft Demand, Tariffs With Margin Gains, Confirms Full-Year Forecast
Ecolab Inc. (NYSE:ECL) reported Q1 sales of $3.69 billion, down 2% Y/Y and missing consensus estimate of $3.70 billion. Organic sales grew 3% Y/Y.
-
2 years ago benzinga.com
Ecolab Q3 Earnings: Beats On EPS, Misses On Sales, Revises Annual EPS Forecast & More (CORRECTED)
Ecolab reported lower Q3 sales growth of 1%, missing consensus estimate. Organic sales up 4%, operating income up 17%. Revised FY24 outlook.
-
2 years ago benzinga.com
Why Waste Management Shares Are Diving Today
Waste Management reported worse-than-expected Q2 FY24 results, with sales of $5.402B and adjusted EPS of $1.82. Free cash flow increased 41.1%.
-
2 years ago benzinga.com
Waste Management To Acquire Stericycle For $62.00/Share In Cash, At 20% Premium
Waste Management agreed to acquire Stericycle, adding medical waste & document shredding services. Both stocks have seen gains in past 12 months.
-
2 years ago benzinga.com
Waste Management Mulls $3B Sale Of RNG Business: Report
Waste Management is seeking to sell its renewable natural gas business for about $3 billion. The company is working with JPMorgan to gauge interest from potential buyers.